Skip to main content
Premium Trial:

Request an Annual Quote

Genomic Health Q2 Revenues Swell 75 Percent on Strong Oncotype DX Sales

NEW YORK (GenomeWeb News) - Genomic Health yesterday said second-quarter revenues grew by 75 percent, R&D spending rose 93 percent, and net loss widened by 47 percent.
Total receipts for the three months ended June 30 increased to $14.7 million from $8.4 million year over year.
Product revenues jumped 87 percent to $14.6 million, while contract revenue decreased 76 percent to $135,000 million. CEO Randy Scott said product revenues from sales of the company’s Oncotype DX test were "stronger than our expectations," and that the firm made "important reimbursement progress" over the quarter.
R&D spending swelled to $5.2 million from $2.7 million in the year-ago period.
Net loss for the second quarter increased to $7.2 million from $4.9 million.
Genomic Health said it had around $43.6 million in cash and cash equivalents, and $36.1 million in short-term investments as of June 30.
Genomic Health said its revenue for the full year "may be at the high end” of the guidance it provided in January of between $57 million and $63 million. The company’s projected loss for the full year remains unchanged, between $27 million and $30 million.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.